Arch Therapeutics Inc (ARTH)

[NNW]

The ability to renegotiate corporate debt to less onerous terms indicates the company is less speculative to the lending institution. Good sign (and good management). The S-3 filing appears to be shelf registration. As they have a decent amount of cash currently, the shelf paper seems a precursor to next year. Dr. Norchi has said FDA application should be 2017. So this indicates ARTH is confident to go through application process on their own. Perhaps some people prefer that ARTH be bought out by someone like J&J. And, yes, it is fun when you see shares of a company you own increasing 50% or 100% on the news. But I have much higher expectations for ARTH. I'll take the 50 or 100% if they are bought out early, but I believe they are poised for much greater returns.